Clinical Trial Update: Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating veliparib with topotecan and G-CSF support in persistent or recurrent cervical cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Adenosquamous Carcinoma
• Cervical Cancer
• Cervical Carcinoma
• Cervical Small Cell Carcinoma
• Cervical Squamous Cell Carcinoma
• Stage Iva Cervical Cancer
• Stage Ivb Cervical Cancer

Drugs mentioned

• Filgrastim (filgrastim)
• Pegfilgrastim (pegfilgrastim)
• Topotecan hydrochloride (topotecan hydrochloride)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-01